Top

Cancer Chemotherapy and Pharmacology

Published in:

01-01-2012 | Original Article

Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor

Authors: Dongchun Wang, Feng Tang, Sen Wang, Zhenzhou Jiang, Luyong Zhang

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2012

Abstract

Objective

SIM010603 is a structurally novel, oral, multi-targeted receptor tyrosine kinase inhibitor. This study investigated the anti-angiogenic and anti-tumor effects of SIM010603.

Methods

A radiometric protein kinase assay was used for measuring the kinase activity of the 32 protein kinases. Receptor phosphorylation was determined by enzyme-linked immunosorbent assay (ELISA). Cell proliferation was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Cell chemotaxis was evaluated by modified Boyden chamber assay. Effect of SIM010603 on angiogenesis was examined by mouse cornea angiogenesis assay. Effect of SIM010603 on xenografts was assessed by tumor growth delay. Effects of SIM010603 on tumor microvascular density (MVD), recruitment of pericytes, and pericyte encapsulation of tumor vessels were analyzed by immunofluorescent staining technique.

Results

SIM010603 inhibited stem cell factor receptor (Kit), vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β), glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), and Fms-like tyrosine kinase-3 (FLT3) with IC₅₀ values between 5.0 and 68.1 nmol/l. SIM010603 inhibited the phosphorylation of PDGFR-β and VEGFR-2. Moreover, SIM010603 inhibited endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis. Although SIM010603 exhibited lower activity in regard to proliferation of NCI-H460, MDA-MB-435, and T241-VEGF-A cells (IC₅₀ > 1 μmol/l), SIM010603 inhibited tumor growth in these xenograft tumor growth models. SIM010603 reduced tumor MVD in T241-VEGF-A tumor xenograft models and decreased positive signals of CD31, NG2 in MDA-MB-435, and LLC-SW-44 xenograft tumor models.

Conclusions

These results support the clinical assessment of SIM010603 as a therapeutic agent for cancer.

Available only for authorised users

Gatzemeier U, Blumenschein G, Fosella F, Simantov R, Elting J, Bigwood D et al (2006) Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 24(Suppl):364s

Hurwitz H, Fehrenbacher L, Novotny W, Cripe L, McGuire W, Wertheim M et al (2007) Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenousleuk aemia (AML), and multiple myeloma (MM). J Clin Oncol 25(Suppl):160s

Ross RW, Stein M, Sarantopoulos J, Eisenberg P, Logan T, Srinivas S et al (2007) A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC). J Clin Oncol 25(Suppl):658s

Tibes R, Trent J, Kurzrock R (2005) Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Ann Rev Pharmacol Toxicol 45:357–384CrossRef

Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:355–365PubMedCrossRef

Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330–1340PubMedCrossRef

Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117–125PubMedCrossRef

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 101:13306–13311PubMedCrossRef

Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445–2459PubMedCrossRef

10.

Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRef

11.

Petrelli A, Giordano S (2008) From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 15(5):422–432PubMedCrossRef

12.

Ocanal A, Serrano R, Calero R, Pandiella A (2009) Novel tyrosine kinase inhibitors in the treatment of cancer. Curr Drug Targets 10(6):575–576CrossRef

13.

Cao R, Xue Y, Hedlund EM, Zhong Zh, Tritsaris K, Tondelli B, Lucchini F et al (2010) VEGFR1—mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc Natl Acad Sci 107:856–861PubMedCrossRef

14.

Hedlund EM, Hosaka K, Zhong ZH, Cao R, Cao Y (2009) Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc Natl Acad Sci 106:17505–17510PubMedCrossRef

15.

Sanghera J, Li R, Yan J (2009) Comparison of the luminescent ADP-Glo assay to a standard radiometric assay for measurement of protein kinase activity. Assay Drug Dev Technol 7(6):615–622PubMedCrossRef

16.

Roberts WG, Whalen PM, Soderstrom E, Moraski G, Lyssikatos JP, Wang HF et al (2005) Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673, 451. Cancer Res 65(3):957–966PubMed

17.

Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V et al (1998) Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci 95:14389–14394PubMedCrossRef

18.

Labrecque L, Lamy S, Chapus A, Mihoubi S, Durocher Y, Cass B et al (2005) Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis 26:821–826PubMedCrossRef

19.

Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y (2001) Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci 98:6390–6395PubMedCrossRef

20.

Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309PubMedCrossRef

21.

Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932–936PubMedCrossRef

22.

Chen F, Xue Y, Cao Y, Han B (2009) Cancer-associated systemic syndrome (CASS): the mechanism of VEGF in tumor-bearing mice. Chin J Lung Cancer 12(4):30–35

23.

Xue Y, Religa P, Cao R, Hansen AJ, Lucchini F, Jones B et al (2008) Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci 105(47):18513–18518PubMedCrossRef

24.

Sun L, Tran N, Tang F, App H, Hirth P, McMahon G et al (1998) Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem 41(14):2588–2603PubMedCrossRef

25.

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Schreck RE et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMed

26.

O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KWH et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605PubMedCrossRef

27.

SUTENT (sunitinibmalate) prescribing information (2006) Pfizer. Inc., New York

28.

Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR et al (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276:955–960PubMedCrossRef

29.

Sun L, Tran N, Liang C, Tang F, Rice A, Schreck R et al (1999) Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem 42(5):5120–5130PubMedCrossRef

30.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMedCrossRef

31.

Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276–1312PubMedCrossRef

32.

Zhang XH, Lin LP, Ding J (2006) Platelet-derived growth factor receptor and cancer. Chin Bull Life Sci 18(3):220–226

33.

Tallquist M, Kazlauskas A (2004) PDGF signaling in cells and mice. Cytokine Growth Factor Rev 15(4):205–213PubMedCrossRef

34.

Vincent L, Rafii S (2004) Vascular frontiers without borders: multifaceted roles of platelet-derived growth factor (PDGF) in supporting postnatal angiogenesis and lymphangiogenesis. Cancer Cell 6:307–309PubMedCrossRef

35.

Yao VJ, Sennino B, Davis RB et al (2006) Combined anti-VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models. Presented at the 18th EORTC–NCI–AACR symposium, Prague, Czech Republic, 7–10 November 2006

Title: Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor
Authors: Dongchun Wang
Feng Tang
Sen Wang
Zhenzhou Jiang
Luyong Zhang
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-011-1681-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates

The marine sponge toxin agelasine B increases the intracellular Ca2+ concentration and induces apoptosis in human breast cancer cells (MCF-7)

Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy

Montelukast attenuates side effects of cisplatin including testicular, spermatological, and hormonal damage in male rats

In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin

Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer